Mallinckrodt Medical, Inc.

Medibeacon Inc.

Mallinckrodt, Inc.

Liebel-flarsheim Company LLC

Guerbet

Curium US LLC

Mallinckrodt Nuclear Medicine LLC

Dennis A Moore

Raghavan Rajagopalan

Richard Bradley Dorshow

Rebecca A Wallace

Scott T Depierro

William L Neumann

David H White

Steven R Woulfe

Muthunadar P Periasamy

Edward A Deutsch

T Jeffrey Dunn

Lynn A deLearie

Milorad M Rogic

Michael R Hynes

William P Cacheris

Stephen R Cooper

Max D Adams

Muthanadar P Periasamy

Rebacca A Wallace

William J Neubert

Wayne H Lin

In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.

Methods of using optical agents

Process for using optical agents

The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. Xto Xof Formulas I and II may be characterized as electron withdrawing groups, while Yto Yof Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient. 

Fluorescent pyrazine derivatives and methods of using the same in assessing renal function

The present disclosure relates generally to a process for the synthesis of 1,4,7,10-tetraazacyclododecane ligands, chelates, and derivatives thereof. In particular, the present disclosure is directed to a process for the synthesis of 1,4,7,10-tetraaza-1,4,7,10-tetrakis(carboxymethyl)cyclododecane (DOTA) ligands, corresponding DOTA-metal chelates, and various derivatives thereof.

Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates

Injection systems and related methods including an injection device, an operator interface, and modules to determine operational parameters during an MRA imaging procedure. Such parameters may be used to optimize and/or maximize signal intensity during an MRA imaging procedure. The injection system may include a target in-bloodstream contrast agent concentration determination module that determines a target in-bloodstream contrast agent concentration at least partially based on contrast agent type and MRA imager parameters. The injection system may include a contrast agent injection rate determination module that determines a contrast agent injection rate at least partially based on the target in-bloodstream contrast agent concentration, an initial contrast agent concentration, and a cardiac output rate of a patient to be imaged. The injection system may include a diluent injection rate determination module that determines a diluent injection rate at least partially based on the contrast agent injection rate.

Method to determine contrast media injection parameters to control signal intensity during magnetic resonance angiography

The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. Xto Xof Formulas I and II may be characterized as electron withdrawing groups, while Yto Yof Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. 

The present disclosure relates generally to a process for the synthesis of 1,4,7,10 -tetraazacyclododecane ligands, chelates, and derivatives thereof. In particular, the present disclosure is directed to a process for the synthesis of 1,4,7,10-tetraaza-1,4,7,10-tetrakis(carboxymethyl)cyclododecane (DOTA) ligands, corresponding DOTA-metal chelates, and various derivatives thereof.

A compound comprising a metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent is provided. The compound is suitable for imaging by single-photon emission computed tomography, computer assisted tomography, magnetic resonance spectroscopy, magnetic resonance imaging, positron emission tomography, fluorescence imaging or x-ray.

Version of FDG detectable by single-photon emission computed tomography

Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent

The present invention relates to pyrazine derivatives represented by Formula I. Xand Xof Formula I may be characterized as electron withdrawing groups, while Yand Yof Formula I may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may be capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient 

Improved methods for synthesizing bifunctional chelates of tetraazamacrocycle derivatives and intermediates thereof are disclosed as well as novel tetraazamacrocycle derivatives and intermediates thereof.

Metal complexes of tetraazamacrocycle derivatives

This invention is directed to the general method of transforming non-photoactive bioactive small molecule compounds of known structure and function into photoactive analogs of the small molecules which exhibit both photoactivity and the original biological targeting activity. The general method for the design of the photoactive analogs of the small molecules includes: (a) selecting a desired bioactive molecule; (b) identifying the region of the molecule that contains an aromatic or a heteroaromatic motif; and (c) either replacing said motif with a photoactive functional group of similar size, or modifying said motif to make it photoactive. Other aspects include photoactive analog compounds and photodiagnostic and phototherapeutic uses thereof.

Growing community of inventors

St. Louis, MO, United States of America

Dennis A Moore